Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.
- Presentation
Hidradenitis Suppurativa: The latest on biologic and small molecule therapies
Description
The presentation discusses treatment options for Hidradenitis Suppurativa (HS), focusing on biologics like TNF inhibitors such as adalimumab and infliximab, which are standards for moderate to severe cases. The efficacy rates for these drugs demonstrate that about half of patients achieve significant improvement, yet some may experience a waning response over time, necessitating careful monitoring and dose adjustments. Alternative treatments include other TNF inhibitors like certolizumab and non-TNF biologics such as IL-17 inhibitors and JACK inhibitors, which are emerging as possible options but require more data for validation. The speaker emphasizes the importance of a combined approach, coordinating medication with surgical interventions for optimal management. There is a significant underutilization of available therapies among eligible HS patients, and the need for effective communication between dermatologists and other healthcare providers is highlighted. Overall, while challenges remain in treating HS, the landscape of available therapies is expanding, offering hope for effective management of the disease.
View moreConclusions
- Adalimumab is considered the gold standard biologic treatment for hidradenitis suppurativa (HS), with about 50% of patients achieving a significant improvement.
- Infliximab is the most effective biologic for HS and requires high doses and frequent administration for optimal response.
- Patients may experience waning efficacy over time while on biologic treatments, necessitating frequent re-assessment and possible dosage adjustments.
- Anti-drug antibodies may develop and contribute to treatment failure, and testing for these may be necessary to optimize therapy.
- Biosimilars can result in loss of response or adverse events, highlighting caution when switching from original biologics to their biosimilars.
- Emerging therapies, including IL-17 inhibitors and JAK inhibitors, show promise for HS treatment but require more data for widespread use.
- Individualized treatment plans that may combine medical and surgical interventions are crucial for managing HS effectively.
- Despite current treatment challenges, many patients can achieve improvement with the right therapies, emphasizing ongoing hope and treatment options.
- J Am Acad Dermatol. 2009;61(1):51-57.
- N Engl J Med 2016; 375: 422-34.
- Br J Dermatol. 2019 Nov;181(5):967-975.
- J Am Acad Dermatol. 2019 Sep;81(3):702-708.
- J Am Acad Dermatol. 2020 May;82(5):1094-1161.
- J Dermatolog Treat. 2012;23:28499.
- Br J Dermatol. 2021 Oct;185(4):863-865.
- J Clin Med. 2022 Feb 15;11(4):1007.
- Life (Basel). 2022 Sep 29;12(10):1518.
- Biomedicines. 2022 Oct 9;10(10):2522.
- Dermatol Ther. 2022 Nov;35(11):e15803.
- JAMA Dermatol. 2021;157:708.
- JAAD Case Rep. 2020 Dec 17;8:77-79.
- JAMA Dermatol. 2016 Jan;152(1):52-59.
- J Invest Dermatol. 2020 Aug;140(8):1538-1545.
- J Am Acad Dermatol. 2024 Mar;90(3):521-529.
- J Am Acad Dermatol. 2022 Dec;87(6):1440-1442.
- Ther Adv Chronic Dis. 2021 Nov 23;12:20406223211055920.
- JAMA Surg. 2021 Nov 1;156(11):1001-1009.